Booth, TC.; Wiegers, EC.; Warnert, EAH.; Schmainda, KM.; Riemer, F.; Nechifor, RE.; Keil, VC.... (2022). High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics. Frontiers in Oncology. 11:1-22. https://doi.org/10.3389/fonc.2021.811425
Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/194942
Título:
|
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics
|
Autor:
|
Booth, Thomas C.
Wiegers, Evita C.
Warnert, Esther A. H.
Schmainda, Kathleen M.
Riemer, Frank
Nechifor, Ruben E.
Keil, Vera C.
Hangel, Gilbert
Figueiredo, Patrícia
Álvarez-Torres, María del Mar
Henriksen, Otto M.
|
Fecha difusión:
|
|
Resumen:
|
[EN] ObjectiveTo summarize evidence for use of advanced MRI techniques as monitoring biomarkers in the clinic, and to highlight the latest bench-to-bedside developments. MethodsThe current evidence regarding the potential ...[+]
[EN] ObjectiveTo summarize evidence for use of advanced MRI techniques as monitoring biomarkers in the clinic, and to highlight the latest bench-to-bedside developments. MethodsThe current evidence regarding the potential for monitoring biomarkers was reviewed and individual modalities of metabolism and/or chemical composition imaging discussed. Perfusion, permeability, and microstructure imaging were similarly analyzed in Part 1 of this two-part review article and are valuable reading as background to this article. We appraise the clinic readiness of all the individual modalities and consider methodologies involving machine learning (radiomics) and the combination of MRI approaches (multiparametric imaging). ResultsThe biochemical composition of high-grade gliomas is markedly different from healthy brain tissue. Magnetic resonance spectroscopy allows the simultaneous acquisition of an array of metabolic alterations, with choline-based ratios appearing to be consistently discriminatory in treatment response assessment, although challenges remain despite this being a mature technique. Promising directions relate to ultra-high field strengths, 2-hydroxyglutarate analysis, and the use of non-proton nuclei. Labile protons on endogenous proteins can be selectively targeted with chemical exchange saturation transfer to give high resolution images. The body of evidence for clinical application of amide proton transfer imaging has been building for a decade, but more evidence is required to confirm chemical exchange saturation transfer use as a monitoring biomarker. Multiparametric methodologies, including the incorporation of nuclear medicine techniques, combine probes measuring different tumor properties. Although potentially synergistic, the limitations of each individual modality also can be compounded, particularly in the absence of standardization. Machine learning requires large datasets with high-quality annotation; there is currently low-level evidence for monitoring biomarker clinical application. ConclusionAdvanced MRI techniques show huge promise in treatment response assessment. The clinical readiness analysis highlights that most monitoring biomarkers require standardized international consensus guidelines, with more facilitation regarding technique implementation and reporting in the clinic.
[-]
|
Palabras clave:
|
High-grade glioma
,
Glioblastoma
,
Treatment response
,
Monitoring biomarker
,
MRI
,
Spectroscopy
,
CEST
,
Radiomics
|
Derechos de uso:
|
Reconocimiento (by)
|
Fuente:
|
Frontiers in Oncology. (eissn:
2234-943X
)
|
DOI:
|
10.3389/fonc.2021.811425
|
Editorial:
|
Frontiers Media SA
|
Versión del editor:
|
https://doi.org/10.3389/fonc.2021.811425
|
Código del Proyecto:
|
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50009%2F2020/PT
...[+]
info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F50009%2F2020/PT
info:eu-repo/grantAgreement/NWO//18144/
info:eu-repo/grantAgreement/NWO//91619121/
info:eu-repo/grantAgreement/EPSRC//WT 203148%2FZ%2F16%2FZ/
info:eu-repo/grantAgreement/COST//CA18206/
info:eu-repo/grantAgreement/FWF//KLI-646/
info:eu-repo/grantAgreement/AEI//DPI2016-80054-R//BIOMARCADORES DINAMICOS BASADOS EN FIRMAS TISULARES MULTIPARAMETRICAS PARA EL SEGUIMIENTO Y EVALUACION DE LA RESPUESTA A TRATAMIENTO DE PACIENTES CON GLIOBLASTOMA Y CANCER DE PROSTATA/
info:eu-repo/grantAgreement/NCI//R01 CA255123/
info:eu-repo/grantAgreement/NCI//U01 CA176110/
info:eu-repo/grantAgreement/NCI//UG3 CA247606/
info:eu-repo/grantAgreement/Universitatea Babes-Bolyai//35277%2F18.11.2020/
[-]
|
Agradecimientos:
|
This publication is part of the COST Action CA18206 Glioma
MR Imaging 2.0 (www.glimr.eu), supported by COST (European
Cooperation in Science and Technology), www.cost.eu. GliMR provided travel and accommodation for members ...[+]
This publication is part of the COST Action CA18206 Glioma
MR Imaging 2.0 (www.glimr.eu), supported by COST (European
Cooperation in Science and Technology), www.cost.eu. GliMR provided travel and accommodation for members who had
travelled to early networking meetings.
- KS: National Institute of Health/National Cancer Institute R01
CA255123, U01 CA176110, UG3 CA247606, Medical College
of Wisconsin Cancer Center.
- GH: Austrian Science Fund grant KLI-646.
- ECW: The Dutch Research Council (NWO) Talent Programme
Veni: 18144
- EAHW: The Dutch Research Council (NWO) Talent Programme
Veni: 91619121
- PF: The Portuguese Foundation for Science and Technology (FCT)
Grant UIDB/50009/2020.
- RN: Babes-Bolyai University, Grant GTC No. 35277/18.11.2020.
- TB: The Wellcome/EPSRC Centre for Medical Engineering
[WT 203148/Z/16/Z].
- MA¿
-T: The ALBATROSS project (National Plan for Scientific
and Technical Research and Innovation 2017-2020 and
DPI2016-80054-R (Programa Estatal de Promocio¿n del
Talento y su Empleabilidad en I+D+i).
[-]
|
Tipo:
|
Artículo
|